Actelion and GlaxoSmithKline enter into exclusive collaboration to realise the full potential of almorexant in sleep disorders

Actelion and GlaxoSmithKline (GSK) to potentially co-develop and co-commercialise other orexin receptor antagonists

15-Jul-2008

Actelion Ltd and GlaxoSmithKline announced that they have entered into an exclusive worldwide collaboration (excluding Japan) for Actelion's almorexant, an orexin receptor antagonist in phase III development with first-in-class potential as a treatment for primary insomnia.

Under the terms of the agreement, GSK will receive exclusive worldwide rights to co-develop and co-commercialise almorexant. Actelion will continue to lead the ongoing development programme and potential registration for almorexant in the first indication, primary insomnia, with GSK contributing 40 per cent of the costs. Almorexant will also be studied in other orexin-related disorders and all costs related to these programmes will be shared equally.

Actelion will receive an upfront payment of CHF 150 million (approximately £66 million) and will be eligible for additional potential milestone payments of up to CHF 415 million in regards to the successful development and approval of almorexant in primary insomnia.In addition, Actelion will be eligible to receive additional milestone payments, pending successful development of two other major indications for almorexant yet to be evaluated through clinical investigation. If all three indications were successfully registered, approved and commercialised, and exceptional sales targets met for all these indications, Actelion would be eligible to receive additional potential milestone payments of up to CHF 2.735 billion. Also, costs and profits resulting from this collaboration will be shared equally between the two companies.

https://www.bionity.com/en/news/84750/actelion-and-glaxosmithkline-enter-into-exclusive-collaboration-to-realise-the-full-potential-of-almorexant-in-sleep-disorders.html